NEW YORK (GenomeWeb) – Quidel has received 510(k) clearance from the US Food and Drug Administration for a molecular assay for the qualitative detection of Clostridium difficile.

The test runs on the firm's Solana platform and generates results in about 35 minutes from unformed stool specimens without a nucleic acid extraction step. The platform can process up to 12 different assays or patient samples in each batched run and uses the firm's helicase-dependent amplification technology, which is also the core technology of Quidel's AmpliVue molecular product line.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.